关键词：心肌梗死；心脏肌肉；形成阻塞；组织损害
摘 要：Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation of plaque (a substance made of fat, cholesterol, and cellular waste), the heart is starved of oxygen, a condition called cardiac ischemia, causing tissue damage. Cardiac ischemia may lead to episodes of angina or chest pain. The slow build-up of plaque on the walls of the heart narrows the blood vessels and finally blocks them. Rapid flow of lipids through the vessels may also create a tear on the walls of the vessels causing aggregation of platelets and the formation of a clot. The clot formation causes obstruction of blood supply through the vessels, leading to necrosis or the death of tissues in the heart muscle.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Key buying criteria

PART 05: Disease overview

Types of myocardial infarction

Pathophysiology

Risk factors

Diagnosis

Management

PART 06: Epidemiology and economic burden

Burden of disease

PART 07: Pipeline analysis

Canakinumab

MyoCell

MultiStem therapy

CLBS10

Prochymal

Revascor

CicloMulsion

PP-099

NP202

CAP-1002

Revacept

CSL112

PART 08: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 09: Market segmentation by drug class

Beta blockers

ACE inhibitors

ARBs

Vasodilators

Antithrombotic agents

Thrombolytics

Glycoprotein IIb/IIIa inhibitors

Anti-dyslipidemic drugs

Calcium channel blockers

Analgesics

PART 10: Market segmentation by EKG appearance

NSTEMI

STEMI

PART 11: Market segmentation by type

Brand-name drugs

Generic drugs

PART 12: Geographical segmentation

Global myocardial infarction drugs market segmentation

by geography 2015-2020

Myocardial infarction drugs market in Americas

Myocardial infarction drugs market in EMEA

Myocardial infarction drugs market in APAC

PART 13: Market drivers

Increase in older population

Sedentary lifestyle

Rise in obesity

High prevalence of chronic conditions

PART 14: Impact of drivers

PART 15: Market challenges

Delayed diagnosis

Alternative therapies

Extensive use of generics

PART 16: Impact of drivers and challenges

PART 17: Market trends

Growing awareness of disease

Strategic alliances

Increased R&D

Prevalent use of stent grafts

PART 18: Vendor landscape

Competitive scenario

AstraZeneca

Bayer HealthCare

Eli Lilly

Novartis

Pfizer

Sanofi

Other prominent vendors

PART 19: Appendix

List of abbreviations

PART 20: Explore Technavio